Clinical and Safety Outcomes Associated With Treatment of Acute Venous Thromboembolism

Abstract

Using meta-analytic pooling, there were no statistically significant differences for efficacy and safety associated with most treatment strategies used to treat acute venous thromboembolism compared with the LMWH-vitamin K antagonist combination. However, findings suggest that the UFH-vitamin K antagonist combination is associated with the least effective strategy and that rivaroxaban and apixaban may be associated with the lowest risk for bleeding.

Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b′x Domain

“…Laser-induced Injury-Injury to a cremaster arteriolar (30 -50-m diameter) vessel wall was induced with a MicroPoint laser system (Photonics Instruments, Chicago, IL) focused through the microscope objective, parfocal with the focal plane and tuned to 440 nm through the dye cell containing 5 mM coumarin in methanol (13). Data were captured digitally from two fluorescence channels, 488/520 nm and 647/670 nm.…”

“…Quercetin-3-rutinoside, as an inhibitor of PDI, is a potential antithrombotic agent that may prove useful for thromboprophylaxis (12). All currently employed anticoagulant and antiplatelet agents, whether administered orally or parenterally, are associated with bleeding complications (13). The ability to quickly reverse their antithrombotic effects in the face of bleeding complications ensures their safe use.…”

Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Deep Venous Thrombosis and Pulmonary Embolism in the Outpatient Setting: Comparative Economic Evaluation

“…These assumptions were based on patients in studies investigating apixaban, dabigatran, or rivaroxaban referenced by Castellucci and others 5 in their systematic review and meta-analysis examining the efficacy and safety of pharmaceuticals used to prevent recurrent VTE.…”

“…To estimate pharmaceutical-specific outcome rates for the first Markov cycle, we pooled the findings of studies presented in Castellucci and others 5 investigating apixaban, dabigatran, or rivaroxaban. In the following summary of these studies, the percentage of fatal events is presented in parentheses after rates of recurrent PE and major bleeding events.…”

Use of new anticoagulants for the treatment of venous thromboembolism in the context of the results of the XALIA study — clinical trials and routine clinical practice

“…One should also take into account the level of such recommendations [2B] indicating the clinical suggestion. The above-mentioned level of recommendations arises out of the fact that the majority of phase 3 studies that were conducted met the criteria of non-inferiority studies [43][44][45]. However, as can be seen on the basis of the presented analysis and the results of the XALIA study, the recommendation of the 2016 ACCP consensus is also confirmed by the results obtained in the routine clinical practice.…”